BIOLASE Adds Two New Independent Directors to Its Board

BIOLASE Adds Two New Independent Directors to Its Board 
Paul Clark, Former Chairman, CEO, and President of ICOS Corporation
and Former President of the Pharmaceuticals Division of Abbott
Laboratories, and Jeffrey Nugent, Former President and CEO of Both
Neutrogena and Revlon, Join Board of Directors 
IRVINE, CA -- (Marketwired) -- 03/03/14 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, including the Company's proprietary WaterLase(R), and a
pioneer in laser surgery in other medical specialties, as well as a
distributor of digital radiography, intra oral scanners, and
chair-side milling machines and 3-D printers for dentistry, today
announced that the Board of Directors (the "Board") has appointed
Paul Clark and Jeffrey Nugent to the Board. Dr. Alexander K. Arrow
and Dr. Sam Low tendered their resignations from the Board on
February 28, 2013. As a result of these appointments and
resignations, BIOLASE's Board currently consists of six directors,
five of whom are independent directors.  
Paul Clark served as Chairman, CEO, and President of ICOS Corporation
from 1999 to 2007, which was acquired by Lilly in 2007 for $2.2
billion. He directed ICOS from a research organization into a leading
biotechnology company including researching, developing, and
marketing Cialis. From 1984 to 1998, Mr. Clark worked at Abbott
Laboratories ("Abbott") as the President of the Pharmaceuticals
Division and retiring as an Abbott board member and Executive Vice
President. Sales of the Pharmaceuticals Division icreased from $250
million to $2.6 billion during his tenure as President. 
Mr. Clark said, "BIOLASE's technology leadership, dominant market
position, valuable patent portfolio, and product pipeline make it an
exciting opportunity." 
Mr. Clark received a B.A. in finance from the University of Alabama
and an M.B.A from Dartmouth College. He is currently a board member
of Agilent Technologies, Inc., Catalent, and Cerevast Therapeutics. 
Jeffrey Nugent has been President and CEO of Neutrogena and Revlon as
well as Chief Executive Officer, Chairman and Board Member in global
health, personal and beauty care companies across a wide range of
strategic situations. His passion is overcoming growing pains. 
Most recently, Mr. Nugent was Founder, President and CEO of Precision
Dermatology, a multi-channel skin care company that was acquired by
Valeant Pharmaceuticals in February 2014. 
Mr. Nugent said, "I'm delighted to be a part of BIOLASE. The
combination of the Company's market leadership position, unique
technology, and focus on their customers represents an outstanding
growth opportunity." 
Mr. Nugent began his career with Johnson & Johnson and progressed in
increasing responsibilities in finance, operations, marketing,
research and development as well as becoming corporate Vice President
for Global Quality. He led the acquisition of Neutrogena and became
worldwide President and CEO during its high growth phase of becoming
one of the most respected personal care brands in the world.
Following this he became President and CEO of Revlon. At Revlon he
led a turnaround in financial stability and new product innovation.  
Mr. Nugent served as an artillery officer in the U.S. Army and was
stationed at the Pentagon in Intelligence/Operations Research working
directly with the Central Intelligence Agency and the National
Security Agency. He has both a B.S. degree in mathematics and an
M.B.A. in finance and marketing. 
"I am thrilled to have both Paul Clark and Jeff Nugent join the Board
of BIOLASE. They both bring outstanding levels of business knowledge
and formidable management skills that will serve our shareholders
well in the coming years" said Federico Pignatelli, Chairman and
Chief Executive Officer. "As BIOLASE is poised to expand its business
beyond its current core base in dentistry, it will require the depth
and experience in planning and execution that both skillfully
possess." 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment, CAD/CAM intraoral scanners, and in-office
milling machines and 3D printers; products that are focused on
technologies that advance the practice of dentistry and medicine. The
Company's proprietary laser products incorporate approximately 300
patented and patent-pending technologies designed to provide
biologically clinically superior performance with less pain and
faster recovery times. Its innovative products provide cutting-edge
technology at competitive prices to deliver the best results for
dentists and patients. BIOLASE's principal products are revolutionary
dental laser systems that perform a broad range of dental procedures,
including cosmetic and complex surgical applications, and a full line
of dental imaging equipment. BIOLASE has sold more than 25,000
lasers. Other laser products under development address ophthalmology
and other medical and consumer markets. 
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at www.biolase.com, Facebook at
www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc,
Pinterest at www.pinterest.com/biolase, LinkedIn at
www.linkedin.com/company/biolase, Google+ at
www.google.com/+BIOLASEIrvine, Instagram at
www.instagram.com/biolaseinc and YouTube at
www.youtube.com/biolasevideos. 
BIOLASE(R) and WaterLase(R) are registered trademarks of BIOLASE,
Inc. 
For further information, please contact: 
Michael Porter
Porter, LeVay & Rose, Inc. 
212-564-4700 
 
 
Press spacebar to pause and continue. Press esc to stop.